Geographic Preferences: North America, Europe
Tracy Saxton co-founded Pivotal BioVenture Partners, a new venture capital firm backed by a single Chinese investor and targeting early-stage drug companies with its inaugural $300 million fund.
Prior to that, she served as Investment Director at Roche Venture Fund. She joined Roche Venture Fund in 2015 as an Investment Director, leading and managing direct equity investments in biotechnology companies.
She also serves on the Board of Directors of Mission Therapeutics, Millendo Therapeutics and SutroVax and is a Board Observer for Afferent Pharmaceuticals & Biodesy Inc. Prior to joining RVF, Dr. Saxton was at SV Life Sciences Advisers where she was involved in the financings of multiple biopharmaceutical companies including Ophthotech (OPHT), Catabasis (CATB), PanOptica, Sutro Biophama, Thesan and Rempex (acquired by the Medicines Company).
Dr. Saxton previously held positions at Tularik/Amgen, Threshold Pharmaceuticals, and Geron Corp. She began her career as a drug discovery scientist and moved to leadership roles in global regulatory affairs, clinical development, business development and project management.
Dr. Saxton was also a project leader for development programs in HIV/immunotherapy, urology, and oncology, spanning preclinical through Phase 3 of development.
Dr. Saxton earned her PhD in Medical Genetics from the University of Toronto and her MBA from Columbia University and was a Damon Runyon-Walter Winchell Cancer Fund fellow at University of California, San Francisco.